Clinical trial
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
NCT00003107 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00003107 |
|---|---|
| Title | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors |
| Official title | A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer and 1 more |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12 |
| Start date | Oct 1, 1997 |
| First posted | Apr 6, 2004 |
| Last update posted | Sep 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: